Loading clinical trials...
Loading clinical trials...
An Open, Non-randomized, Single-centre, Parallel Group Trial Investigating the Steady-state Blood Concentration Profile and Effects of Once Daily Subcutaneously Injected Recombinant Human Growth Hormone (Norditropin® SimpleXx®) in Patients With End Stage Renal Disease Receiving Chronic Haemodialysis and in Matched Healthy Subjects
Conditions
Interventions
somatropin
somatropin
Locations
1
Germany
Novo Nordisk Investigational Site
München, Germany
Start Date
June 1, 2005
Primary Completion Date
November 1, 2005
Completion Date
November 1, 2005
Last Updated
January 24, 2017
NCT07310264
NCT06290258
NCT00090662
NCT07241390
NCT06716502
NCT07483606
Lead Sponsor
Novo Nordisk A/S
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions